FI118653B - Menetelmä peptisen haavan riskin määrittämiseksi - Google Patents

Menetelmä peptisen haavan riskin määrittämiseksi Download PDF

Info

Publication number
FI118653B
FI118653B FI990992A FI990992A FI118653B FI 118653 B FI118653 B FI 118653B FI 990992 A FI990992 A FI 990992A FI 990992 A FI990992 A FI 990992A FI 118653 B FI118653 B FI 118653B
Authority
FI
Finland
Prior art keywords
gastrin
pepsinogen
gastritis
risk
concentration
Prior art date
Application number
FI990992A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI990992A0 (fi
FI990992A (fi
Inventor
Osmo Suovaniemi
Matti Haerkoenen
Pentti Sipponen
Erik Forsblom
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Publication of FI990992A0 publication Critical patent/FI990992A0/fi
Priority to FI990992A priority Critical patent/FI118653B/fi
Priority to DK00922684T priority patent/DK1173770T3/da
Priority to EP00922684A priority patent/EP1173770B1/en
Priority to AU42998/00A priority patent/AU4299800A/en
Priority to ES00922684T priority patent/ES2241597T3/es
Priority to CN00808720.2A priority patent/CN100573152C/zh
Priority to US09/959,551 priority patent/US6872543B1/en
Priority to AT00922684T priority patent/ATE300053T1/de
Priority to PT00922684T priority patent/PT1173770E/pt
Priority to RU2001132335/15A priority patent/RU2225615C2/ru
Priority to PCT/FI2000/000377 priority patent/WO2000067035A1/en
Priority to DE60021369T priority patent/DE60021369T2/de
Priority to JP2000615822A priority patent/JP4598959B2/ja
Publication of FI990992A publication Critical patent/FI990992A/fi
Application granted granted Critical
Publication of FI118653B publication Critical patent/FI118653B/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seal Device For Vehicle (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI990992A 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi FI118653B (fi)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FI990992A FI118653B (fi) 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi
US09/959,551 US6872543B1 (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen I (PGI) and gastrin-17 in a serum sample
PT00922684T PT1173770E (pt) 1999-04-30 2000-04-28 Metodo para estimar o risco de ulcera peptica
AU42998/00A AU4299800A (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
ES00922684T ES2241597T3 (es) 1999-04-30 2000-04-28 Metodo para valorar el riesgo de ulcera peptica.
CN00808720.2A CN100573152C (zh) 1999-04-30 2000-04-28 评估患消化性溃疡的危险度的方法,包括定量测定血清样品中胃蛋白酶原i(pgi)和胃泌素-17的浓度的步骤
DK00922684T DK1173770T3 (da) 1999-04-30 2000-04-28 Fremgangsmåde til vurdering af risikoen for mavesår
AT00922684T ATE300053T1 (de) 1999-04-30 2000-04-28 Verfahren zur abschätzung eines magengeschwür- risikos
EP00922684A EP1173770B1 (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer
RU2001132335/15A RU2225615C2 (ru) 1999-04-30 2000-04-28 Способ дифференциации между наличием риска образования язвы желудка и язвы двенадцатиперстной кишки
PCT/FI2000/000377 WO2000067035A1 (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
DE60021369T DE60021369T2 (de) 1999-04-30 2000-04-28 Verfahren zur Abschätzung eines Magengeschwürrisikos
JP2000615822A JP4598959B2 (ja) 1999-04-30 2000-04-28 血清サンプル中のペプシノーゲンｉ（ｐｇｉ）とガストリン−１７の濃度の定量的測定の段階を含む、消化性潰瘍の危険性を評価する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI990992A FI118653B (fi) 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi
FI990992 1999-04-30

Publications (3)

Publication Number Publication Date
FI990992A0 FI990992A0 (fi) 1999-04-30
FI990992A FI990992A (fi) 2000-10-31
FI118653B true FI118653B (fi) 2008-01-31

Family

ID=8554567

Family Applications (1)

Application Number Title Priority Date Filing Date
FI990992A FI118653B (fi) 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi

Country Status (13)

Country Link
US (1) US6872543B1 (ja)
EP (1) EP1173770B1 (ja)
JP (1) JP4598959B2 (ja)
CN (1) CN100573152C (ja)
AT (1) ATE300053T1 (ja)
AU (1) AU4299800A (ja)
DE (1) DE60021369T2 (ja)
DK (1) DK1173770T3 (ja)
ES (1) ES2241597T3 (ja)
FI (1) FI118653B (ja)
PT (1) PT1173770E (ja)
RU (1) RU2225615C2 (ja)
WO (1) WO2000067035A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019A (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2450898A1 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
SE0200974D0 (sv) * 2002-03-27 2002-03-27 Phagen Ab Screening method for gastritis
FI119571B (fi) * 2002-09-06 2008-12-31 Biohit Oyj Menetelmä esofagiitin tai Barrettin ruokatorven riskin osoittamiseksi yksilöllä
JP4689597B2 (ja) * 2003-03-28 2011-05-25 レセプター バイオロジックス インク． ガストリンホルモン免疫アッセイ
FI119572B (fi) * 2004-03-05 2008-12-31 Biohit Oyj Menetelmä vatsan limakalvon tilan ennustamiseksi
WO2005095459A2 (en) * 2004-03-29 2005-10-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
US8272265B2 (en) * 2005-07-12 2012-09-25 Technion Research And Development Foundation Ltd. System and method for active detection of asymmetry in rotating structures
CN101910844A (zh) * 2007-10-26 2010-12-08 拜奥希特公司 用于诊断与萎缩性胃炎相联系的自身免疫性疾病和胃癌的方法和产品
RU2465597C1 (ru) * 2011-04-08 2012-10-27 Сергей Михайлович Котелевец Способ определения вероятности развития рака желудка
RU2582565C1 (ru) * 2015-03-06 2016-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации /ГБОУ ВПО ОрГМУ Минздрава России/ Способ дифференциальной диагностики язвы желудка и двенадцатиперстной кишки
CN104820096B (zh) * 2015-04-30 2017-04-19 必欧瀚生物技术（合肥）有限公司 一种判断早期胃癌风险检测用标志物的量的联合标准量及在筛查早期胃癌方面的应用
CN107271669A (zh) * 2016-09-23 2017-10-20 清华大学深圳研究生院 胃蛋白酶原、抗幽门螺杆菌抗体和胃泌素17检测方法及其试剂盒
CN107328938A (zh) * 2016-09-23 2017-11-07 清华大学深圳研究生院 胃蛋白酶原和抗幽门螺杆菌抗体检测方法及其试剂盒
JP6885581B2 (ja) * 2017-02-06 2021-06-16 学校法人東京歯科大学 ガストリン測定におけるカットオフ値の推定方法
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
RU2677228C1 (ru) * 2017-12-08 2019-01-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Способ иммунодиагностики заболеваний гастродуоденальной зоны

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07304800A (ja) * 1994-05-06 1995-11-21 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk ヒトペプシノゲンに対するモノクローナル抗体
FI97304C (fi) * 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi
JP2949474B2 (ja) * 1995-08-28 1999-09-13 隆久 古田 ペプシノーゲンｉ／ｉｉ比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法
JPH10148636A (ja) * 1996-11-15 1998-06-02 Takahisa Furuta ペプシノーゲン ｉ／ｉｉ 比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法

Also Published As

Publication number Publication date
AU4299800A (en) 2000-11-17
US6872543B1 (en) 2005-03-29
ATE300053T1 (de) 2005-08-15
DE60021369D1 (de) 2005-08-25
PT1173770E (pt) 2005-09-30
EP1173770A1 (en) 2002-01-23
CN100573152C (zh) 2009-12-23
DK1173770T3 (da) 2005-08-08
FI990992A0 (fi) 1999-04-30
WO2000067035A1 (en) 2000-11-09
CN1355888A (zh) 2002-06-26
JP2002543433A (ja) 2002-12-17
FI990992A (fi) 2000-10-31
EP1173770B1 (en) 2005-07-20
DE60021369T2 (de) 2006-05-24
ES2241597T3 (es) 2005-11-01
RU2225615C2 (ru) 2004-03-10
JP4598959B2 (ja) 2010-12-15

Similar Documents

Publication Publication Date Title
FI118653B (fi) Menetelmä peptisen haavan riskin määrittämiseksi
EP0804737B1 (en) Method for screening the risk of gastric cancer
RU2262706C2 (ru) Способ для диагностики атрофических гастритов
Karnes Jr et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis
Stein et al. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function
RU2462719C2 (ru) Диагностика септических осложнений
US20150126401A1 (en) Calprotectin and hemoglobin/haptoglobin complex from stool sample to assess colorectal cancer
Charrier et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two‐dimensional electrophoresis
US5552292A (en) Method of screening for colorectal cancer
EP1552311B1 (en) Method for detecting a risk of acid related disease in an individual
US20080162101A1 (en) Method for Predicting the State of the Gastric Mucosa
Griffiths et al. Comparison of enzyme-linked immunosorbent assay and radioimmunoassay for prostate-specific acid phosphatase in prostatic disease.
Sasaki et al. Elevated plasma thymosin-� 1 levels in lung cancer patients
Goldenberg et al. A critical evaluation of a specific radioimmunoassay for prostatic acid phosphatase
Gredal et al. The Lundh test and faecal elastase 1 determination in chronic pancreatitis: a comparative study
US20060199230A1 (en) Use of prostate specific antigen to predict drug response
CA2414590A1 (en) Methods for monitoring treatment of helicobacter infection and for predicting the likelihood of successful eradication
WO2003029826A1 (en) Method for detecting a cancer or precancerous condition
KR20180117918A (ko) Mfap5 측정 제제를 포함하는 대장암 진단용 조성물, 키트, 및 이를 이용한 대장암 진단 방법
Erger et al. Comparison of methodologies to measure human lung histamine
IT202100019616A1 (it) Nuovo metodo
sive Droste et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: Faecal Immunochemical Test versus Guaiac-based Faecal Occult Blood Test
FI20215799A1 (en) Combined GastroPanel in one microplate
JPH0933521A (ja) 炎症性疾患の検査方法および検査薬
WO1999023491A1 (en) Diagnosis of guillain barre syndrome or cancer by detecting integrin alpha6/beta4

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118653

Country of ref document: FI